Non-Metastatic CRPC in the Era of PSMA PET Imaging: Challenges and Opportunities – Aaron Berger
Zach Klaassen and Aaron Berger explore the evolving landscape of non-metastatic castration-resistant prostate cancer (CRPC). Dr. Berger highlights the decreasing frequency of non-metastatic CRPC in clinical settings, attributing this shift to advanced imaging techniques, especially PSMA PET scans, which more accurately detect metastatic stages. He notes that in 2022 and 2023, only about 8% of…